Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

1.170 -0.120 (-9.30%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis

June 14, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

June 02, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Recap: Aldeyra Therapeutics Q1 Earnings ↗

May 04, 2023

Via Benzinga

Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights

May 04, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Earnings Outlook For Aldeyra Therapeutics ↗

March 08, 2023

Via Benzinga

R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

May 02, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

Via FinancialNewsMedia

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 01, 2023

Via Benzinga

The Week In Charts: 0DTE Options - Too Good To Be True? ↗

April 30, 2023

Zero-days; how Core Methodology can be used in Crypto, with current Crypto and stock market conditions; favorite stock picks.

Via Talk Markets

Short Volatility Alert: Aldeyra Therapeutics ↗

April 28, 2023

On Thursday, shares of Aldeyra Therapeutics (NASDAQ: ALDX) experienced volatile short activity. After the activity, the stock price went down -0.22% to $9.05. The overall sentiment for ALDX has been...

Via Benzinga

OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay ↗

April 18, 2023

Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA).

Via Benzinga

Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis

April 13, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Chart Of The Day: Aldeyra - Skyrocketing ↗

April 11, 2023

Revenue is expected to grow by 2,045.80% next year. Earnings are estimated to increase by 16.90% next year and continue to compound at an annual rate of 73.70% for the next 5 years.

Via Talk Markets

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) Records 52-Week High Monday Morning

April 10, 2023

Via Investor Brand Network

Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis

April 06, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough

March 30, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4 ↗

March 28, 2023

Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...

Via Benzinga

BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗

March 27, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

UBS, Credit Suisse And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

March 24, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday ↗

March 23, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa

March 16, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

March 09, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma

March 02, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights

March 01, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients ↗

February 28, 2023

Via Benzinga

Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease

February 28, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough ↗

February 23, 2023

An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...

Via Benzinga

Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy

February 23, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials

February 16, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

February 09, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

February 07, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.